Compare Crispr Therapeutics AG (CRSP) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Hut 8 Corp — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Hut 8 Corp trades at $84.27 (market cap $9.82B). The key difference: Hut 8 Corp is far larger — about 2× Crispr Therapeutics AG's market cap, and Hut 8 Corp is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Hut 8 Corp for 11 Days on average.
| CRSP | HUT | |
|---|---|---|
Market Cap | $4.88B | $9.82B |
Volume | 2,861,747 | 10,272,678 |
Sector | Health | Financials |
52-Week High | $74.92 | $133.02 |
52-Week Low | $44.34 | $33.76 |
Typical Hold Time | 77 Days | 11 Days |
Enterprise Value | $3.30B | $17.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
HUT trades at $79.59, down 10.87% today, amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a -188.59% net income margin and has missed earnings expectations for three consecutive quarters. Recent positive developments include securing a $1.07 billion credit facility and growing institutional interest, positioning the company in the expanding AI infrastructure market.
While analyst consensus remains strongly bullish with a $162.69 price target, significant risks persist including ongoing losses, high valuation multiples, and competitive pressures in AI infrastructure. The stock's outlook hinges on successful execution of its business transformation and achieving profitability amid substantial capital investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
